Dynavax reports Q3 EPS 21c vs. 12c last year

Reports Q3 revenue $94.88M, consensus $94M. “In Q3 2025, we delivered important progress across our strategic initiatives, including advancing our commercial, clinical, and capital allocation objectives. HEPLISAV-B continued its impressive performance, further solidifying its market share leading position in the U.S. adult hepatitis B vaccine market,” said Ryan Spencer, CEO. “Our vaccine pipeline continues to progress, with key clinical milestones achieved or expected this year across multiple programs and now supplemented with our first late-stage business development deal – an exclusive license agreement with Vaxart for its oral vaccine candidate for COVID-19. Beyond our operational successes, we are also strategically deploying capital to both expand our long-term growth opportunities, as evidenced by our new license agreement, and to return value to shareholders through our newly authorized $100M share repurchase program, reflecting our confidence in Dynavax’s (DVAX) future and commitment to a balanced capital allocation strategy.”